U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H14ClF2N3O3S
Molecular Weight 413.826
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PLX-4720

SMILES

CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(Cl)C=C23)=C1F

InChI

InChIKey=YZDJQTHVDDOVHR-UHFFFAOYSA-N
InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)

HIDE SMILES / InChI

Description

PLX-4720 is a pre-clinical analog of vemurafenib which selectively targets BRAFV600E. PLX-4720 was developed by Plexxikon for the treatment of thyroid cancer, however the drug did not reach clinical phase.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
13.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Mice were given PLX-4720 at a dose of 30 mg/kg/day.
Route of Administration: Oral
In Vitro Use Guide
Human thyroid carcinoma cell lines 8505c, TPC-1, and NT cells were treated with 1 or 10 uM of PLX-4720 during 72 hours. At 1 uM the drug caused significant reduction in cell prolifiration.